Eagle Asset Management’s Theravance Biopharma TBPH Stock Holding History

Eagle Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-278,626	Closed	-$3.63M	–	675
2015 Q2	$3.63M	Sell	278,626 -9,906	-3%	-$154K	0.02%	486
2015 Q1	$5.01M	Sell	288,532 -320	-0.1%	-$5.87K	0.03%	428
2014 Q4	$4.31M	Sell	288,852 -165,622	-36%	-$2.89M	0.02%	447
2014 Q3	$10.5M	Sell	454,474 -13,406	-3%	-$389K	0.06%	319
2014 Q2	$14.9M	Buy	+467,880	New	+$14.1M	0.08%	280

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FAM

Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

Eagle Asset Management's TBPH Position: Q3 2015 in Review

Eagle Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2015, closing a stake of 278,626 shares — an estimated $3.63M sold.

Eagle Asset Management first reported a position in TBPH in Q2 2014 and held it in 5 quarters. The position peaked at $14.9M in Q2 2014. 83 funds tracked by Wall St. Rank hold TBPH as of Q3 2015.

Eagle Asset Management reported no remaining Theravance Biopharma position as of Q3 2015 after selling out during the quarter.
Eagle Asset Management sold 278,626 Theravance Biopharma shares in Q3 2015, an estimated $3.63M.
Eagle Asset Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 5 quarters.
Eagle Asset Management's Theravance Biopharma position peaked at $14.9M in Q2 2014.
83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2015.

Based on Eagle Asset Management's 13F filing for Q3 2015, filed 20 Oct 2015.